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Abstract
In the last 15 years, highly active antiretroviral therapy (HAART) has determined a dramatic 
reduction of both morbidity and mortality in human immunodeficiency virus (HIV)
subjects, transforming this infection in a chronic and manageable disease.
with HIV in the developed world, in larger number men,  are becoming aged. As it would be 
expected for a population of comparable age, many HIV
history  of  cardiovascular  disease,  a  small  proportion  h
cardiovascular event and an increasing proportion has diabetes mellitus. Smoking rate is very 
high while an increasing proportion of HIV
suggest that these traditional risk factors 
cardiovascular disease in these patients as they do in the general population. Thus, whilst the 
predicted 10-year cardiovascular disease risk remains relatively low at present, it will likely 
increase in relation to the progressive aging of  this patient population. Thus, the long
follow-up  of  HIV  infected  patients  has  to  include  co
cardiovascular  disease  prevention  and  treatment.  Two  intriguing  aspects  related  to  the 
cardiovascular risk in patients with HIV infection are the matter of current investigation: 1) 
while these subjects share many cardiovascular risk factors with the general population, HIV 
infection  itself  increases  cardiovascular  risk;  2)  some  HAART  regimens  t
atherosclerotic profile, partly due to lipid changes. Although the mechanisms involved in the 
development  of  cardiovascular  complications  in  HIV
elucidated,  treatment  guidelines  recommending  interventions  t
disease in these individuals are already available; however, their application is still limited. 
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In the last 15 years, highly active antiretroviral therapy (HAART) has determined a dramatic 
reduction of both morbidity and mortality in human immunodeficiency virus (HIV)
subjects, transforming this infection in a chronic and manageable disease.
with HIV in the developed world, in larger number men,  are becoming aged. As it would be 
expected for a population of comparable age, many HIV-infected individuals report a family 
history  of  cardiovascular  disease,  a  small  proportion  have  already  experienced  a 
cardiovascular event and an increasing proportion has diabetes mellitus. Smoking rate is very 
high while an increasing proportion of HIV-infected individuals have dyslipidaemia. Studies 
suggest that these traditional risk factors could play an important  role in the development of 
cardiovascular disease in these patients as they do in the general population. Thus, whilst the 
year cardiovascular disease risk remains relatively low at present, it will likely 
relation to the progressive aging of  this patient population. Thus, the long
up  of  HIV  infected  patients  has  to  include  co-morbidity  management  such  as 
cardiovascular  disease  prevention  and  treatment.  Two  intriguing  aspects  related  to  the 
iovascular risk in patients with HIV infection are the matter of current investigation: 1) 
while these subjects share many cardiovascular risk factors with the general population, HIV 
infection  itself  increases  cardiovascular  risk;  2)  some  HAART  regimens  t
atherosclerotic profile, partly due to lipid changes. Although the mechanisms involved in the 
development  of  cardiovascular  complications  in  HIV-infected  patients  remain  to  be  fully 
elucidated,  treatment  guidelines  recommending  interventions  to  prevent  cardiovascular 
disease in these individuals are already available; however, their application is still limited. 
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In the last 15 years, highly active antiretroviral therapy (HAART) has determined a dramatic 
reduction of both morbidity and mortality in human immunodeficiency virus (HIV)-infected 
subjects, transforming this infection in a chronic and manageable disease. Patients surviving 
with HIV in the developed world, in larger number men,  are becoming aged. As it would be 
infected individuals report a family 
ave  already  experienced  a 
cardiovascular event and an increasing proportion has diabetes mellitus. Smoking rate is very 
infected individuals have dyslipidaemia. Studies 
could play an important  role in the development of 
cardiovascular disease in these patients as they do in the general population. Thus, whilst the 
year cardiovascular disease risk remains relatively low at present, it will likely 
relation to the progressive aging of  this patient population. Thus, the long-term 
morbidity  management  such  as 
cardiovascular  disease  prevention  and  treatment.  Two  intriguing  aspects  related  to  the 
iovascular risk in patients with HIV infection are the matter of current investigation: 1) 
while these subjects share many cardiovascular risk factors with the general population, HIV 
infection  itself  increases  cardiovascular  risk;  2)  some  HAART  regimens  too  influence 
atherosclerotic profile, partly due to lipid changes. Although the mechanisms involved in the 
infected  patients  remain  to  be  fully 
o  prevent  cardiovascular 
disease in these individuals are already available; however, their application is still limited. Medit J Hemat Infect Dis 2010; 2(3); Open Journal System 
Introtuction: The  advent  of  highly  active 
antiretroviral  therapy  (HAART),  providing 
sustained  suppression  of  viral  replication  and 
preservation of immune system function, has made 
human  immunodeficiency virus  (HIV) infection  a 
chronic and manageable disease for many patients.
1
The  increased  life  expectancy  and  the  effects  of 
HAART  have  changed  the  management  of  HIV 
infection: medical treatment is no longer limited to 
HIV  infection  but  also  includes  the  control  of 
metabolic,  cardiovascular,  liver,  bone  and  kidney 
complications.
In  particular,  understanding  the  risk  of 
cardiovascular disease (CVD) in persons with HIV 
infection is complex. Controversies exist as to how 
much such risk can be attributed to host genetics, 
traditional  risk  factors,  adverse  effects  from 
antiretroviral  therapy  or  the  inflammatory  state 
associated  with  HIV  itself.
2 Thus,  all  factors 
potentially  contributing  to  CVD  need  to  be 
considered  when  managing  persons  infected  with 
HIV (Figure 1). 
In the last 25 years, a deep and increasing effort 
to  study  HIV  infection  has  been  performed  by  a 
multidisciplinary  approach:  infectious  disease 
physicians,  epidemiologists,  cardiologists  and 
oncologists participated to this work with different 
expertises  and  expectations.  Cross-checking  in 
Pubmed the words “cardiovascular risk” and “hiv” 
or “cardiovascular risk” and “antiretroviral therapy” 
for each single year from 1985 until now, it is clear 
that there has been an increasing interest at first in 
the  relationship  between  HIV  infection  itself  and 
cardiovascular  risk  and  then,  from  1996  - when 
HAART  became  a  standard  for  HIV-positive 
patients- between  antiretroviral  therapy  and 
cardiovascular risk (Figure 2). It is just shortly after 
the  introduction  of  HAART,  that  case  reports  of
myocardial  infarction  (MI)  and  early  vascular 
atherosclerotic  lesions  in  young  patients  infected
Figure 1. Cardiovascular risk in HIV-positive subjects can be attributed to host genetics, traditional risk factors, adverse effects from 
antiretroviral therapy or the inflammatory state associated with HIV itself.Medit J Hemat Infect Dis 2010; 2(3); Open Journal System 
Figure 2. “Cardiovascular risk factors” AND “HIV” OR “antiretroviral therapy” citations in PubMED from 1986 until July 2010.
with  HIV  were  published.
3 Although  the  initial 
focus was primarily on the protease inhibitors (PI), 
suggesting  that  lipodystrophy  and  its  related 
metabolic  disorders  could  increase  cardiovascular 
risk,
4 a  broader  appreciation  of  the  complex 
interplay between traditional risk factor
and HIV infection has emerged more recently. 
Several groups of investigators have designed 
studies  to  examine  various  aspects  of  the 
relationship  between  HIV  infection,  traditional 
cardiovascular risk factors, HAART, and short
longer-term  cardiovascular  risk.
5-10
included  both  clinical  end  points  (MI, 
hospitalization  for  MI  or  angina,  and 
revascularization)  and  surrogate  markers  of 
atherosclerosis  (endothelial  function  or  carotid 
intima-media  thickness).  Further  studies  have 
included  data  on  traditional  risk  factors,  longer 
follow-up, and diverse patient populations. 
Methodological  Limitations:  The  difficulties  in 
determining  risks  among  patients  with  HIV 
infection  have  largely  been  due  to  the  lack  of 
matched  controls,  small  sample  size,  and  lack  of 
standardized  definitions,  besides  the  unknown 
contribution  from  HIV  itself.  Often,  data  sources 
developed for other purposes have been used for a 
better  understanding  of  the  association  between 
HIV and CVD. These studies vary in  end 
methods  of  end-point  collection  and  validation, 
degree to which data on traditional risk factors were 
captured, and the amount of information available 
about the type and duration of HAART exposure. 
When HIV-negative control groups were included, 
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“Cardiovascular risk factors” AND “HIV” OR “antiretroviral therapy” citations in PubMED from 1986 until July 2010.
Although  the  initial 
focus was primarily on the protease inhibitors (PI), 
suggesting  that  lipodystrophy  and  its  related 
metabolic  disorders  could  increase  cardiovascular 
a  broader  appreciation  of  the  complex 
interplay between traditional risk factors for CVD 
and HIV infection has emerged more recently. 
Several groups of investigators have designed 
studies  to  examine  various  aspects  of  the 
relationship  between  HIV  infection,  traditional 
cardiovascular risk factors, HAART, and short- and 
10 Studies  have 
included  both  clinical  end  points  (MI, 
hospitalization  for  MI  or  angina,  and 
revascularization)  and  surrogate  markers  of 
atherosclerosis  (endothelial  function  or  carotid 
media  thickness).  Further  studies  have 
luded  data  on  traditional  risk  factors,  longer 
up, and diverse patient populations. 
The  difficulties  in 
determining  risks  among  patients  with  HIV 
infection  have  largely  been  due  to  the  lack  of 
mple  size,  and  lack  of 
standardized  definitions,  besides  the  unknown 
contribution  from  HIV  itself.  Often,  data  sources 
developed for other purposes have been used for a 
better  understanding  of  the  association  between 
HIV and CVD. These studies vary in  end points, 
point  collection  and  validation, 
degree to which data on traditional risk factors were 
captured, and the amount of information available 
about the type and duration of HAART exposure. 
negative control groups were included, 
they  were  often  not  matched  for  important, 
traditional risk factors that may be more prevalent 
in HIV groups, such as smoking. Studies including 
HIV and non HIV-infected control subjects should 
indeed contain complete information on traditional 
risk  factors,  including  smoking,  to  assess  the 
relative contribution of these risk factors to CVD 
rates  and  to  determine  whether  HIV 
marker for patients with increased traditional CVD 
risk  markers.  Despite  methodological  limitations 
inherent to the use of pre-existing or administrative 
databases,  some  consistent  research  themes  have 
emerged in this area, namely, that traditional CVD 
risk  factors  and  relative  CVD  disease  rates  are 
increased  in  HIV-infected  patients,  although 
absolute rates remain low in the 
Global  Cardiovascular  Risk 
Subjects: Unfortunately,  the  principal  studies  in 
this area are not reliable from a cardiology point of 
view: a recent  attempt by our group to perform a 
meta-analysis  confirmed  the  great   
existing on this topic (Table 1).
view, every attempt to perform a meta
not be useful until controlled clinical trials will be  
performed  with  a  tight  collaborations  between 
cardiologists  and  infectivologists,  wi
monitoring and treatment of all cardiovascular risk 
factors and with a careful definition and analysis of 
cardiovascular  events.  Too  much  confounding 
factors do not allow to properly analyze the weight 
of antiretroviral therapy compared to oth
cardiovascular  risk  factors  in  the  development  of 
cardiovascular events. 
1994 1998 2002 2006
“Cardiovascular risk factors” AND “HIV” OR “antiretroviral therapy” citations in PubMED from 1986 until July 2010.
hey  were  often  not  matched  for  important, 
traditional risk factors that may be more prevalent 
in HIV groups, such as smoking. Studies including 
infected control subjects should 
indeed contain complete information on traditional 
,  including  smoking,  to  assess  the 
relative contribution of these risk factors to CVD 
rates  and  to  determine  whether  HIV  per  se is  a 
marker for patients with increased traditional CVD 
risk  markers.  Despite  methodological  limitations 
existing or administrative 
databases,  some  consistent  research  themes  have 
emerged in this area, namely, that traditional CVD 
risk  factors  and  relative  CVD  disease  rates  are 
infected  patients,  although 
absolute rates remain low in the HIV population.
Cardiovascular  Risk  in  HIV-Infected 
Unfortunately,  the  principal  studies  in 
this area are not reliable from a cardiology point of 
view: a recent  attempt by our group to perform a 
analysis  confirmed  the  great    confusion 
Table 1). From this point of 
view, every attempt to perform a meta-analysis will  
not be useful until controlled clinical trials will be  
performed  with  a  tight  collaborations  between 
cardiologists  and  infectivologists,  with  a  careful 
monitoring and treatment of all cardiovascular risk 
factors and with a careful definition and analysis of 
cardiovascular  events.  Too  much  confounding 
factors do not allow to properly analyze the weight 
of antiretroviral therapy compared to other defined 
cardiovascular  risk  factors  in  the  development  of 
2010
HIV
ARTMedit J Hemat Infect Dis 2010; 2(3); Open Journal System 
Table 1. Attempt of a meta-analysis of clinical cardiovascular events in HIV-positive subjects: 11 populations including 145,448 
HIV-positive patients presented 4,207 clinical events.
AMI=acute myocardial infarction, CVD=cerebrovascular diseases, CAD=coronary artery disease
However, certain studies have shown that there may 
be  increased risk of  CVD in  HIV-infected  versus 
uninfected populations (Table 2). Discordant results 
have been however obtained, which possibly reflect 
differences  in  end-point  definitions  and 
ascertainment  or  differences  in  underlying 
cardiovascular  risk  in  the  various  populations 
studied. Klein and collaborators
10 provided one of 
the first reports comparing rates of hospitalization 
for  CVD  in  HIV-infected  adults  with  that  of 
uninfected  control  subjects.  These  Authors  have 
demonstrated that HIV patients have a higher risk of  
hospitalizations for CVD and specifically for acute 
MI relative to HIV-uninfected controls. Currier et 
al
5 observed  an  increased  incidence  of  CVD  in 
younger HIV-infected men and women as compared 
to  HIV- uninfected  recipients.  One  more  recent
Table 2. Global  cardiovascular  risk  in  HIV-infected  patients 
compared with HIV-negative subjects
study also reported an excess relative risk of CVD 
among  HIV-infected  adults  compared  with  HIV-
uninfected  control  subjects.  Triant  et  al.
8  in  fact, 
compared MI rates among HIV-infected adults and 
found  higher  rates  of  acute  MIs  in  HIV-infected 
individuals  than  in  HIV-uninfected  adults.  They 
also noted a higher prevalence of conventional risk 
factors  for  CVD,  such  as  hypertension,  diabetes 
mellitus,  and  dyslipidemia,  in  the  HIV-positive 
group,  factors  that  separately  and  especially  in 
combination  could  explain,  at least  in  part,  the 
excessive risk of CVD in the HIV-infected group. 
Traditional  Cardiovascular  Risk  Factors:  It  is 
critical to understand whether increased CVD rates 
are causally linked to HIV-related factors or merely 
reflect differences in the prevalence of underlying 
traditional  risk  factors.  Importantly,  studies  that 
have controlled for these factors have consistently 
shown a significant effect of traditional risk factors 
on  CVD  events  in  HIV-infected  patients.
7-8 Age, 
smoking, hypertension and diabetes mellitus are all 
strong  predictors  of  CVD  risk  in  HIV-infected 
patients.  Additionally,  the  background  prevalence 
rates of these factors in many HIV cohorts are high 
and may, for some, predict  the acquisition of HIV 
infection.  In  particular,  rates  of  smoking  in  HIV 
Studies [references] Year N° Patients Type of event N° Events
Rickerts V. et al. [11] 2000 4,993 AMI 29
Klein D. et al. [10] 2002 4,159 CAD/AMI 72
Holmberg S.D. et al [12] 2002 5,672 AMI/CVD 35
Currier J.S. et al. [5) 2003 28,513 CAD/AMI 1,360
Bozzette S.A. et al. [9] 2003 36,766 CAD/CVD 2,006
Murielle M.K. et al. [13] 2003 34,976 AMI 60
Barbaro G. et al. [14] 2003 1,551 AMI 26
Varriale P. et al. [15] 2003 690 AMI 29
Escaut L. et al. [16] 2003 840 CAD/AMI 17
Triant V.A. et al. [8] 2007 3,851 AMI 189
DAD [7] 2007 23,437 IMA/CVD 384
References [n°]
Event rate per 
1,000 HIV + 
patients
Event rate per 
1,000 HIV -
patients
Klein    [10] 4.3 2.9
Currier  [5] 4.1 3.3
Triant    [8] 11.1 6.9Medit J Hemat Infect Dis 2010; 2(3); Open Journal System 
populations are consistently high and exceed those 
for age-matched controls in several studies.
17-18
According to the results of  DAD (the largest 
multinational  cohort  collecting  data  on  adverse 
effects of anti-HIV drugs), the risk associated with 
protease inhibitor was considerably lower than the 
annual  increase  in  risk  associated  with  advanced 
age,  male  sex  or  current  smoking.
6 In  fact,  the 
cross-sectional analysis on risk factors of the same 
cohort  showed  that  among  17,852  HIV-positive 
patients 25% presented an increased cardiovascular 
risk for age, 51% for smoking, and there was a high 
prevalence of known cardiovascular risk factors.
17
Age: The proportion of HIV-infected patients older 
than  50  years  has  greatly  increased  since  the 
beginning of the epidemic. By 2015, 50% of HIV-
infected  individuals  in  the  United  States  are 
expected to be older than 50 years.
19 The incidence 
and prevalence of HIV infection in older adults is 
rising, with disproportionate increase in women and 
minorities.  Compared  with  younger  adults,  older 
patients  who  have  HIV  are  often  diagnosed  later 
and  may  have  an  accelerated  decline  in  immune 
function.
20 Although the prognosis for older adults 
has  improved  with  the  initiation  of  HAART,
21 a 
higher risk for co-morbid illness remains.
22
Rather than occurring merely as a consequence 
of  extended  survival  among  ART  recipients,  the 
increased rate of CVD may result from accelerate 
biological  aging  imposed  by  HIV  itself  and/or 
antiretroviral  treatments.  Coronary  artery  calcium 
(CAC) has been used to describe the biological age 
of an individual, which may be different from his 
chronological  age.  The  use  of  CAC  provides  an 
objective tool to assess premature biological aging 
in HIV-infected patients.
23 Additionally, a risk score 
that  includes  CAC  and  age  may  be  an  easily 
understandable  measure  of  risk.
24 On  the  other 
hand, asymptomatic, HIV-infected men with long-
lasting  HIV  disease have an  increased prevalence 
and  degree  of  coronary  atherosclerosis  compared 
with non-HIV-infected patients.
25 In treated patients 
who achieve durable suppression of the HIV virus, 
natural  ageing,  drug  specific  toxicity,  lifestyle 
factors,  persistent  inflammation,  and  perhaps 
residual  immunodeficiency  are  all  causally 
associated  with  premature  development  of 
complications  normally  associated  with  ageing, 
including cardiovascular disease.
26
Smoking: Smoking rates range from 35% to 72% in 
clinical  studies  of  HIV-positive  subjects.
18 Over 
85% of HIV-infected individuals in the U.S. have a 
lifetime  history  of  smoking  and  current  cigarette 
smoking  is  highly  prevalent  among  HIV-positive 
persons.  On  average,  HIV-positive  smokers  have 
been smoking for 22.8 years and smoke 16 to 23 
cigarettes  per  day.  Among  HIV-positive  current 
smokers,  most  are  moderately  to  highly  nicotine 
dependent.
27
Diabetes:  Although  guidelines  in  the  general 
population  consider  diabetes  mellitus  (DM)  to  be 
equivalent to coronary heart disease (CHD), there is 
little  information  on  its  association  with  CHD  in 
subjects  infected  with  HIV.  DM  and  preexisting 
CHD  are  both  important  risk  factors  for  CHD 
events in HIV-infected individuals. There is a need 
for targeted interventions to reduce the risk of CHD 
in  both  high-risk  groups  of  HIV-infected 
individuals.
28
Dyslipidemia:  There  is  substantial  evidence  that 
HIV  infection  impacts  on  blood  lipids,  but  the 
interplay between infection, treatment and changes 
in various lipid parameters is complex.
29,30 Initiation 
of multidrug antiretroviral therapy usually results in 
increased lipids. Protease inhibitors tend to induce 
greater  increase  in  total  cholesterol,  low-density 
lipoprotein  cholesterol  (LDL-c)  and  triglyceride 
than non-nucleoside reverse transcriptase inhibitors 
(NNRTI) whereas  nevirapine  has been linked to 
increase  in  high-density  lipoprotein  (HDL-c). 
Protease  inhibitor–induced  cholesterol  changes  at 
least  partly  explain  the  increased  CHD  risk 
observed in treated compared with untreated HIV-
infected people.
31
The  prevalence  of  dyslipidemia,  whether 
genetically  determined  or  influenced  by  HAART 
(elevated triglycerides, total cholesterol, and LDL-
c)  or  HIV  infection  (low  HDL-cholesterol),  is 
consistently higher in HIV groups. 
Metabolic  Syndrome:  A  number of  changes  seen 
with  HIV  infection,  restoration  to  health,  and 
treatment  with  HAART,  including  dyslipidemia, 
diabetes,  increased  body  mass  index  and  waist 
circumference, may present simultaneously in HIV-
infected patients. 
These  factors  are  part  of  the  metabolic 
syndrome. It is debated whether the prevalence of 
the metabolic syndrome is increased among HIV-
infected patients. Our group has observed that HIV-
positive  patients  over  45  years  presented  a 
prevalence of metabolic syndrome  of  49% versus 
31%  among  controls,  taken  from  the  Moli-sani 
cohort
32 of HIV-negative subjects matched for sex, Medit J Hemat Infect Dis 2010; 2(3); Open Journal System 
cardiovascular  risk  factors  and    cancer  (p<0.01) 
(data not published). 
It remains unknown whether the presence of the 
metabolic syndrome  per se confers increased risk 
for  CVD disease in HIV-infected patients beyond 
that  associated  with  individual  risk  factors. 
Furthermore,  metabolic  syndrome  has  several 
features  in  common  with  the  lipodystrophy 
syndrome observed in HIV–positive patients, such 
as  insulin  resistance,  dyslipidaemia  and  fat 
redistribution.
33-35
The  relative  contribution  of  each  of  the 
cardiovascular  risk  factors  depicted  is  similar  in 
HIV-infected  and  uninfected  populations,  which 
suggests  that  these  factors  contribute  to 
cardiovascular  risk  in  a  comparable  way 
irrespective  of  their  HIV  status.  Consistent  with 
this, analyses that compare the observed incidence 
of  CHD  in  HIV-infected  populations  with  that 
predicted  from  risk  equations  developed  in  the 
general population have reported reasonably similar 
outcomes.  Hence,  traditional  cardiovascular  risk 
factors contribute in important ways to the risk of 
CVD in HIV.
Short  and  Long-Term  Antiretroviral  Therapy: 
...From  Bozzette  to  SMART  Through  DAD...
Bozzette  and  his  group
9 reported  that  overall 
mortality due to HIV dramatically declined in the 
early  HAART  era  without  any  increase  in 
admissions  for  cardiovascular  or  cerebrovascular 
events.  Although limited by the  short duration of 
exposure to combination HAART and by possibly 
incomplete capture of events, this study suggested 
that  over  the  short  term, the  benefits  of  HAART 
clearly  outweighed  the  risk  for  CVD.  The  same 
Authors,  more  recently,  confirmed  similar 
conclusions regarding global reduction of mortality 
and  hospitalization  for  CVD  in  patients  with 
exposure to all antiretroviral drug classes.
36
Recently,  several  well-designed  prospective 
studies  have  shed  some  light  on  the  complex 
interactions  between  the  use  of  antiretroviral 
therapy, HIV infection and cardiovascular risk. The 
Strategies  for  Management  of  Antiretroviral 
Therapy  (SMART)  study
37 reported  that 
interruption of antiretroviral therapy was associated 
with  an increased risk of opportunistic disease or 
death. Furthermore, the drug-conservation strategy 
in  the  SMART  trial  was  associated  with  a  60%
increase in the risk of CVD during a mean follow-
up of 16 months only, indicating that effective viral 
suppression  actually  may  reduce  short-term 
cardiovascular risk.
37 The implication of this study 
is  that  short-term  use  of  antiretroviral  therapy 
reduces cardiovascular risk. However, the long-term 
effects  of  such  therapy  on  cardiovascular  disease 
are  unclear; in  this  context the  first report of the 
DAD  study  group  is  interesting:  among  23,437 
patients  who  were  followed  for  a  median  of  4.5 
years, there were 345 myocardial infarction with an 
incidence  of  3,7/1000/year.  Among  these  events 
29% were fatal representing 10% of all the study 
deaths.
6 Thus  increased  exposure  to  PI  was 
associated with an increased risk of MI, a finding 
that  was  partly  explained  by  dyslipidemia.  Thus 
short  or  long-term  risks  of  antiretroviral  therapy 
may differ.
The second DAD report, confirmed the result of 
the first one: MI incidence rate increased in relation 
to increasing antiretroviral therapy exposure with a 
relative risk of 1,16/year of exposure. No data are 
available regarding other longer term associations. 
It  is  interesting  that  the  association  between 
antiretroviral  therapy  exposure  and  cardiovascular 
risk remains after adjusting for age and sex. After 
adjusting  for  cardiovascular  risk  factors,  except 
lipids, patients with PI showed a 16% increase risk 
of MI per year versus 5% per year among patients 
with NNRTI. Further adjustment for lipids reduced 
the increased risk to 10% for PI and eliminated the 
association with NNRTI use
7 (Table 3). 
It is critical to recognize that the magnitude of 
increased  cardiovascular  risk  observed  with  PI  is 
not high, especially as compared with the effect of 
other cardiovascular risk factors. The relative risk
Table 3. Association between cardiovascular risk and HAART: 
it exists?
Retrospective studies 
[references]
Association between 
cardiovascular risk and 
HAART
Klein D. et al. [10] No
Bozzette S.A. et al. [9] No
Mary-Krause M. et al [4] Yes
Currier J.S. et al. [5] Yes
Obel N. et al. [38] yes
Vaughn G. et al [39] yes
Prospective studies (references)
Holmberg S.D. et al [12] yes
DAD [7] yes
Randomized clinical trial 
(references)
SMART [37] noMedit J Hemat Infect Dis 2010; 2(3); Open Journal System 
per  year  of  exposure  to  PI  was  1.16,  which  is 
considerably  smaller  than  the  relative  risk  of 
increasing age, male sex, current smoking or history 
of cardiovascular diseases. 
Recently,  the  DAD  study  unexpectedly  found 
almost a double rate for MI in HIV-infected patients 
treated  with  abacavir,  a nucleoside  reverse 
trascriptase  inhibitor  (NRTI),  for  the  previous  6 
months. The risk associated with abacavir use was 
independent  of  traditional  cardiovascular  risk 
factors and was no longer significant when abacavir 
had  been  stopped  prior  to  the  last  6  months, 
suggesting an ‘on–off ’ mechanism directly induced 
by  abacavir  that  might  involve  biological 
mechanisms  associated  with  atherosclerosis.
40 A 
posthoc analysis of the SMART study also showed 
a  higher  risk  of  cardiovascular  disease,  including 
MI,  in  patients  treated  with  abacavir.
41 These 
patients  had  higher  levels  of  inflammation  and 
hypercoagulability  biomarkers  (interleukin-6,  IL-6 
and high sensitivity C reactive protein, hs-CRP) at 
the  SMART  study  entry.  Abacavir  could  have 
induced  those  pathogenetic  mechanisms,  owing 
proinflammatory properties, that induce flogosis of 
arterial  wall  and  subsequent  instability of  already 
present  plaques.  In  this  way  expression  of  a 
subclinical atherosclerosis could become clinically 
apparent. By contrast, data from naive patients in a 
Glaxo-Smith-Kline (GSK) and Aids Clinical Trial 
Group (ACTG) studies did not show any significant 
difference  regarding  MI  between  abacavir-treated 
and un-treated antiretroviral naive patients.
42,43 The 
potential cardiovascular effects of abacavir might be 
less evident in antiretroviral-naive patients because 
of the confounding noise due to uncontrolled HIV 
replication.  Two  major  sources  of  bias  and 
confounding not controlled for in previous studies, 
such  as  drug  prescription  and  uncontrolled  HIV 
infection, did not affect a more recent study,
44 that 
provided  an  opportunity  to  assess  the  potential 
effects  of  abacavir  on  different  mechanisms 
involved in the pathogenesis of MI as compared to 
other antiretroviral drugs. Such study showed that 
abacavir/lamivudine increased both total and LDL 
cholesterol  compared  with  tenofovir/emtricitabine, 
but  did  not  cause  any  inflammation,  endothelial 
dysfunction,  insulin  resistance,  or 
hypercoagulability in virologically suppressed HIV-
infected patients.
In a recent analysis of DAD data, Worm and 
co-workers
45  examined  the  risk  of  MI  associated 
with  exposure  to  individual  antiretroviral  drugs 
from three major drug classes: the individual drugs 
examined,  namely  indinavir,  lopinavir-ritonavir, 
abacavir, and didanosine were all associated with an 
increased risk of MI.
This risk appeared to increase with cumulative 
exposure  to  the  two  PIs  and  could  partly  be 
explained by dyslipidemia caused by these drugs. In 
contrast, associations between MI risk and abacavir 
and didanosine exposure were largely confined to 
those patients with recent exposure to the drugs and 
did not appear to be driven by dyslipidemia. As the 
overall  rate  of  MI  remains  relatively  low,  any 
toxicities  of  antiretroviral  drugs  must  always  be 
balanced  versus the  benefits  that  these  drugs 
provide. In agreement with these results, Jong and 
colleagues
46  recently  showed  that HIV-infected 
patients  using  abacavir  had  no  specific 
abnormalities  in  coagulation  or  inflammation 
markers that might explain the increased risk of MI. 
For  the  whole  group,  regardless  of  abacavir  use, 
evidence  of  a  pro-thrombotic  state  was  observed. 
Thirty-three percent of patients with long-term use 
of antiretroviral treatment had hs-CRP levels above 
3  mg/L,  which  is  strongly  associated  with 
cardiovascular  disease in  HIV-uninfected 
individuals.
46
Inflammation  and  Endothelial  Function: The 
ACTG 5152 Study
47 had the purpose of evaluating 
the  effects  of  three  HAART  regimens  on 
endothelial  function  in  treatment-naïve  HIV-
infected  subjects  participating  in  a  large, 
prospective, randomized trial. Endothelial function 
was evaluated by measuring flow-mediated dilation 
(FMD) of the brachial artery by B-mode ultrasound. 
Patients  with  HIV  infection  who  met  criteria  for 
starting HAART had impaired endothelial function. 
Use  of  three  different  ART  regimens  rapidly 
improved  endothelial  function  in  treatment-naive 
patients  with  HIV  infection.  Improvement  was 
similar for all HAART regimens, appeared quickly, 
and  persisted  over  24  weeks.  It  is  unclear  if  the 
improvements were due to HAART, suppression of 
viremia, or changes in factors not measured in this 
study,  such  as  immune  activation  or  biological 
variation.
47
A  review  by  our  group
48  compared  different 
studies  on  endothelial  adhesion  molecule  levels 
looking  for  their  increase  or  reduction  during 
HAART. If soluble adhesion molecules (and other 
endothelial cell molecules) are reliable biomarkers 
of pathological endothelial activation by HIV, the 
obvious  corollary  would  be  that  a  beneficial 
treatment  should  lower  their  levels  in  the 
circulation.  Endothelial  dysfunction,  as  measured 
by  circulating  cell  adhesion  molecule Medit J Hemat Infect Dis 2010; 2(3); Open Journal System 
concentrations, should thus be reduced by HAART: 
while HIV infection impact generally increases the 
endothelial  adhesion  molecule  levels,  HAART 
impact, except for some studies, generally reduces 
such levels, suggesting that therapy reduces indeed 
endothelial damage.   
In apparent  contrast with this  last assumption 
and  previous  reports,  we  had  obtained  data 
supporting the hypothesis that HAART does indeed 
induce  activation  of  endothelial  function.  In 
particular,  we  measured  intercellular  adhesion 
molecule-1 (ICAM-1) and P-selectin concentrations 
(as  well as tissue plasminogen activator, tPA and 
plasminogen  activator  inhibitor-1,  PAI-1),  in  a 
group of HIV-positive patients undergoing either PI 
or NNRTI therapy and compared them with naïve 
HIV-positive patients. P-selectin, t-PA, and PAI-1 
levels were all significantly higher in both HAART 
subgroups,  while  ICAM-1  concentrations  did  not 
differ  significantly  from  those  measured  in  the 
naive group. In addition, a positive association was 
seen  between  lipid  levels  and  endothelial 
biomarkers—namely, cholesterol correlated with t-
PA,  P-selectin,  and  ICAM-1,  while  triglycerides 
correlated  with  PAI-1.  We  reasoned  that,  on  one 
hand—by  controlling  HIV  infection—HAART 
should reduce the associated endothelial injury; on 
the other hand—by deranging lipid metabolism—it 
would  contribute  to  stimulating  endothelial 
function.
49
Thus  a  substantial  proportion  of  the  risk 
attributed to PI remains unexplained. Although the 
DAD study demonstrates a relative increase in risk 
with increased duration of HAART, in part due to 
the presence of one or more traditional risk factors, 
the absolute risk of CVD will remain low for most 
patients.  Because  the  absolute  CVD  rates  remain 
low, the relative increase in these rates might not 
have  public  health  significance:  however  this 
situation may change in the future as HIV patients 
will live longer due to successful HAART.
50
C  reactive  protein  (CRP)  is  an  indicator  of 
immune  activation  in  response  to  inflammatory 
damage or infection and has been shown to increase 
in HIV-1–infected individuals. Levels of CRP were 
associated  with  HIV  disease  progression 
independent  of  CD4  lymphocyte  counts  and  HIV 
RNA levels. In addition, regardless of progression 
to AIDS, HIV-infected individuals had a significant 
increase in CRP over time. Fibrinogen and CRP are 
strong  and  independent  predictors  of  mortality  in 
HIV-infected adults. Even in those with relatively 
preserved  CD4  counts  >500  cells  per  microliter, 
inflammation remains an important risk factor for 
mortality.
51,52
The  higher  prevalence  of  premature  carotid 
lesions in the PI-treated patients requires the routine 
introduction of a periodic ultrasonographic study of 
the vascular wall in the follow-up of HIV infected 
patients.
53
The presence of subclinical carotid lesions has 
been shown to highly associate with the estimated 
Framingham Risk Score (p<0.002). The presence of 
subclinical  atheromasic  lesions  was  also  high 
among  antiretroviral-naïve  patients.  HIV  infection 
per se is a risk factor for atherosclerosis. Thus an 
ultrasonographic  assessment  both  among  patients 
with FRS 6% or more and among those in advanced 
stage of disease is required.
54
Viro-Immunological  Features:  The  DAD  study
7 
found no association between either the peak HIV-1 
RNA  level  or  the  nadir  CD4+  lymphocyte  count 
and  the  risk  of  MI,  although  the  possibility  that 
other unmeasured immunologic effects could have 
exerted an influence on the development of CVD 
cannot  be  excluded.  The  Staccato  trial
55  in  fact, 
investigated whether HIV replication modified the 
levels of  plasma soluble inflammatory molecules in 
a  combination  antiretroviral  therapy  interruption 
trial.  Initiation  of  HAART  resulted  in  significant 
declines  in  s-VCAM-1,  P-selectin,  leptin  and  D-
dimer,  whereas  mediators  with  anti-inflammatory 
properties,  such  as  adiponectin  and  IL-10, 
increased.  At  12  weeks  after  randomization,  they 
found  positive  associations  between  levels  of  s-
VCAM-1 and chemokine ligand 2 with an increase 
in plasma HIV-RNA, whereas levels of adiponectin 
decreased  for  each  1  log  increase  in  plasma 
HIVRNA. Plasma levels of  several inflammatory, 
anti-inflammatory  and  endothelial  activation 
markers  of  cardiovascular  disease  are  associated 
with  HIV-RNA  replication.
55 On  the  other  hand, 
Kaplan  and  colleagues
56  observed  that  beyond 
traditional cardiovascular disease risk factors, low 
CD4+ T-cell count is the most robust risk factor for 
increased subclinical carotid atherosclerosis in HIV-
infected women and men.
Co-morbidities: Several studies demonstrated that 
the  presence  of  co-morbidities,  such  as  viral 
hepatitis, renal and bone diseases, could influence 
cardiovascular risk in HIV-positive patients.
57-58
Cardiovascular  Risk  Evaluation: Although  the 
estimation of CVD risk might prove useful both to 
establish the relative contribution of different risk Medit J Hemat Infect Dis 2010; 2(3); Open Journal System 
factors  and  for  clinical  management  in  HIV 
patients, estimates  of  CVD  risk  from  long  term 
observational  studies  are  still  scanty  in  these 
settings,  and  estimates  of  CVD  using  algorithms 
other than Framingham are lacking.
59 De Socio and 
colleagues
60  have recently  used  Framingham  Risk 
Score  as  well  as  three  other  cardiovascular 
algorithms  (‘‘PROCAM’’,  ‘‘PROGETTO 
CUORE’’,  ‘‘SCORE’’)  to  calculate  the  10-year 
probability  of  acute  coronary  events  in  HIV-
positive  patients. The  utilization  of  these  tools to 
identify patients with a worse CV risk profile seems 
to be a promising and simple way for monitoring 
long  term  CVD  risks  in  the  population  of  HIV 
infected  patients,  as  cardiovascular  risk  reduction 
efforts  will  necessarily  rely  on  combined 
interventions, given the multiplicity of risk factors 
involved.
Cardiovascular Risk Management:“Choosing an 
effective antiretroviral regimen has become an art” 
writes Aberg, considering the difficulties to choose 
a  regimen  that  allow  to  obtain  viral  suppression 
without  any  adverse  effect of  HAART  such  as
increased cardiovascular risk.
61
Cardiovascular risk should be evaluated before 
initiation  of  antiretroviral  therapy  and  frequently 
thereafter during follow-up, and decisions to alter 
therapy  on  the  basis  of  adverse  changes  in 
metabolic  risk  factors  should  be  made  on  an 
individual  basis.  Virologic  control  is  the  primary 
goal for HIV-infected persons with cardiovascular 
risk,
62 and  is  the  primary  consideration  in 
determining when to start antiretroviral therapy and 
to  change  regimens.  Current  guidelines  suggest 
treating cardiovascular risk in HIV-infected patients 
in the same manner as recommended for the general 
population.  Management  may  include  dietary  and 
exercise  intervention,  smoking  cessation, 
establishment  of  lipid  goals  and  treatment  of 
dyslipidemia,  while  drug  therapy  (eg,  statins, 
antihypertensives, aspirin) should only be added in 
high-risk  patients  (eg,  those  with  established 
coronary disease, diabetes, or moderate or high risk 
on risk scoring). Switching of antiretroviral therapy 
may be considered, when other methods of treating 
risk are not effective.
Collectively,  the  data  linking  viremia  and 
endothelial  dysfunction  and  inflammation,  the 
increased  risk  of  cardiovascular  events  with 
treatment interruption, and the association between 
cardiovascular  disease  and  CD4  cell  depletion, 
suggest that early control of HIV replication with 
antiretroviral therapy can be used as a strategy to 
reduce cardiovascular disease risk.
63
Conclusions:  As  in  the  general  population, 
individual  cardiovascular  risk  factors  such  as 
hypertension, diabetes, dyslipidemia, and smoking 
have  an  additive  or  synergistic  impact  on  overall 
risk  and  should  be  addressed  at  initiation  of 
antiretroviral therapy and frequently during follow-
up.  Lifestyle  modification  should  be  the  first 
management  approach,  including  smoking 
cessation, diet modification, and increased exercise. 
In  managing  hyperlipidemia,  the  decision  to  use 
lipid-lowering  therapy  or  to  switch  antiretroviral 
therapy  regimens  should  be  individualized.  The
impact  of  smoking  cessation  is  greater  than  the 
impact of any other intervention in reducing overall 
risk,  and  although  cardiovascular  risk  should  be 
considered when starting or changing antiretroviral 
therapy, virologic control should be the overriding 
consideration. 
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